Bristol/Gillette Vaniqa To Be Launched In September For Facial Hair Removal
Executive Summary
Bristol-Myers Squibb is collecting quality of life data to document the psychosocial benefits of the prescription facial hair removal cream Vaniqa.
You may also be interested in...
Women First Vaniqa Focus Is PCOS; Bristol Broad Cosmetic Use Vanquished
Women First HealthCare will pursue managed care reimbursement for Vaniqa by positioning the facial hair removal agent as a treatment for hirsutism associated with polycystic ovary syndrome
Women First Vaniqa Focus Is PCOS; Bristol Broad Cosmetic Use Vanquished
Women First HealthCare will pursue managed care reimbursement for Vaniqa by positioning the facial hair removal agent as a treatment for hirsutism associated with polycystic ovary syndrome
FDA Accepts Drug Quality Of Life Claims From Secondary Endpoints - Bristol
FDA sometimes allows quality of life claims for drugs based on secondary endpoints in clinical trials, Bristol-Myers Squibb Health Economics Policy & External Relations Group Director Joseph Jackson, PhD, told a Drug Information Association meeting March 12 in Washington, D.C.